← Ablatotech Vitals
Otolaryngology EvidenceDigest

Watchful waiting versus antibiotics in acute otitis media

Otolaryngology · EvidenceDigest

Reviewed by the Ablatotech Vitals editorial team
September 23, 2026 · Reviewer: dekema
Educational use only. This digest is AI-curated commentary reviewed by clinicians. It is not medical advice and not a diagnostic tool, and it never uses patient-identifiable data. Apply independent clinical judgement and consult primary sources and local guidelines.

In the management of acute otitis media (AOM), watchful waiting is a viable strategy for many children, particularly those over two years of age with mild symptoms. This approach can reduce unnecessary antibiotic use and its associated risks, such as antibiotic resistance and adv…

# EvidenceDigest: Watchful Waiting versus Antibiotics in Acute Otitis Media

Clinical bottom line

In the management of acute otitis media (AOM), watchful waiting is a viable strategy for many children, particularly those over two years of age with mild symptoms. This approach can reduce unnecessary antibiotic use and its associated risks, such as antibiotic resistance and adverse effects. Antibiotics should be reserved for cases with severe symptoms or in younger children where the risk of complications is higher.

What the evidence shows

Recent guidelines and studies support the use of watchful waiting in select cases of AOM. The American Academy of Pediatrics (AAP) guidelines (2013, reaffirmed in 2019) recommend watchful waiting for children over two years with mild symptoms, as many cases resolve spontaneously without antibiotics (PMID: 23439909). This approach can significantly reduce antibiotic prescriptions without compromising outcomes.

A systematic review by Venekamp et al. (2015) found that while antibiotics can slightly reduce symptom duration and pain in AOM, the benefits are modest, and the risk of adverse effects, such as diarrhea and rash, is increased (PMID: 26329399). This review supports the selective use of antibiotics, emphasizing the importance of clinical judgment.

A randomized controlled trial by Hoberman et al. (2011) demonstrated that immediate antibiotic treatment is more beneficial in children under two years with severe symptoms, reducing symptom duration and the risk of treatment failure (PMID: 21190464). This trial underscores the need for a tailored approach based on age and symptom severity.

Caveats and uncertainty

While watchful waiting is effective for many children, it requires careful patient selection and close follow-up to ensure timely intervention if symptoms worsen. Parents and caregivers should be educated on the signs of complications and the importance of follow-up visits.

The decision to use antibiotics should consider individual patient factors, including age, symptom severity, and risk of complications. Further research is needed to refine criteria for watchful waiting and explore the long-term impact of reduced antibiotic use on resistance patterns.

How this may change practice

The evidence supporting watchful waiting in AOM may lead to its increased adoption in clinical practice, particularly for older children with mild symptoms. This approach aligns with efforts to reduce antibiotic overuse and its associated risks.

Clinicians should engage in shared decision-making with parents, discussing the potential benefits and risks of watchful waiting versus antibiotics. Clear communication and education are essential to ensure adherence to follow-up recommendations and timely intervention if needed.


References

  1. Lieberthal AS, et al. The Diagnosis and Management of Acute Otitis Media. Pediatrics 2013;131:e964-e999. PMID: 23439909 PMID: 23439909
  2. Venekamp RP, et al. Antibiotics for Acute Otitis Media in Children. Cochrane Database Syst Rev 2015;6:CD000219. PMID: 26329399 PMID: 26329399
  3. Hoberman A, et al. Treatment of Acute Otitis Media in Children under 2 Years of Age. N Engl J Med 2011;364:105-115. PMID: 21190464 PMID: 21190464
  4. Note: This EvidenceDigest is for educational purposes only and should not be construed as medical advice.

© 2026 Ablatotech, Inc. All rights reserved. Reviewed by the Ablatotech Vitals editorial team